PanGenomic Health, Inc. Class A (TSE:NARA)
:NARA
Top Page
PanGenomic Health, Inc. Class A
(NARA)
Select Model
Select Model
Rating:42Neutral
Price Target:
C$0.48
▼(-5.88% Downside)
Action:UpgradedDate:12/30/25
The score is held down primarily by very weak financial performance (no revenue, ongoing losses/cash burn, and negative equity). Technicals also remain bearish with the stock below major moving averages and negative MACD. Corporate events provide some support via financing and product/distribution initiatives, but do not offset the underlying profitability and balance-sheet challenges.
Positive Factors
Low reported debt
Zero reported debt in the trailing twelve months reduces near-term refinancing pressure and lowers immediate interest obligations. This durable structural relief gives management more time to execute on commercialization or cost-reduction plans before needing new debt financing, improving short-term solvency.
Negative Factors
No recorded revenue
Absence of recorded revenue across reported periods means the firm's business model remains unproven and product-market fit is unvalidated. Over a multi-month horizon this limits internal cash generation, increases dependence on financing, and heightens execution risk tied to achieving commercial traction.
Read all positive and negative factors
Positive Factors
Negative Factors
Low reported debt
Zero reported debt in the trailing twelve months reduces near-term refinancing pressure and lowers immediate interest obligations. This durable structural relief gives management more time to execute on commercialization or cost-reduction plans before needing new debt financing, improving short-term solvency.
Read all positive factors
PanGenomic Health, Inc. Class A (NARA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$6.67M
Dividend YieldN/A
Average Volume (3M)110.39K
Price to Earnings (P/E)―
Beta (1Y)0.82
Revenue GrowthN/A
EPS Growth81.01%
CountryCA
Employees5
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.11
Shares Outstanding14,046,870
10 Day Avg. Volume77,322
30 Day Avg. Volume110,395
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PanGenomic Health, Inc. Class A Business Overview & Revenue Model
Company Description
Pangenomic Health Inc., a precision health company, develops a self-care digital platform to deliver personalized and evidence-based information about natural treatments to support mental health. It develops the Nara App, a mobile app that provide...
How the Company Makes Money
PanGenomic Health, Inc. generates revenue primarily through subscription services to its digital health platform. Users pay for access to personalized recommendations and insights based on their genomic data. Additionally, the company may earn rev...
PanGenomic Health, Inc. Class A Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
9
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -471.00 | ― | -681.43K | -11.11K | -2.13K | 0.00 |
| EBITDA | -3.37M | ― | -2.71M | -3.57M | -847.50K | -1.81K |
| Net Income | -3.41M | -3.80K | -2.97M | -20.35M | -2.65M | -139.99K |
Balance Sheet | ||||||
| Total Assets | 270.90K | 39.16K | 71.48K | 504.14K | 2.58M | 147.22K |
| Cash, Cash Equivalents and Short-Term Investments | 82.16K | 1.31K | 12.56K | 88.53K | 1.35M | 38.23K |
| Total Debt | 0.00 | 0.00 | 964.75K | 101.77K | 0.00 | 27.50K |
| Total Liabilities | 2.04M | 2.44M | 2.22M | 719.25K | 334.45K | 136.27K |
| Stockholders Equity | -1.77M | -2.41M | -2.14M | -215.11K | 2.24M | 10.95K |
Cash Flow | ||||||
| Free Cash Flow | -1.70M | -58.25K | -1.57M | -2.79M | -1.07M | -37.52K |
| Operating Cash Flow | -1.70M | -58.25K | -1.57M | -2.78M | -1.06M | -37.52K |
| Investing Cash Flow | 0.00 | 0.00 | -3.14K | -52.13K | -604.91K | -100.00K |
| Financing Cash Flow | 1.75M | 47.00K | 1.50M | 1.57M | 2.97M | 173.50K |
PanGenomic Health, Inc. Class A Technical Analysis
Neutral
0.51
Price Trends
0.44
Positive
0.59
Negative
1.09
Negative
Market Momentum
>-0.01
Negative
60.86
Neutral
100.95
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NARA, the sentiment is Neutral. The current price of 0.51 is above the 20-day moving average (MA) of 0.41, above the 50-day MA of 0.44, and below the 200-day MA of 1.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 60.86 is Neutral, neither overbought nor oversold. The STOCH value of 100.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:NARA.
PanGenomic Health, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$52.68M | -2.31 | -207.53% | ― | ― | 7.04% | |
45 Neutral | C$30.71M | -9.48 | 3086.87% | ― | -48.53% | -9.66% | |
45 Neutral | C$3.72M | -4.56 | -34.06% | ― | -100.00% | 65.85% | |
42 Neutral | C$6.67M | -4.68 | ― | ― | ― | 81.01% | |
41 Neutral | C$7.77M | -5.12 | 6239.15% | ― | ― | 48.94% | |
| ― | C$13.14M | -21.40 | 527.45% | ― | ― | -67.11% |
* Healthcare Sector Average
TSE:NARA
PanGenomic Health, Inc. Class A
0.48
0.27
126.19%
TSE:ADK
Diagnos
0.26
-0.02
-5.56%
TSE:NDAT
nDatalyze Corp
0.09
0.07
260.00%
TSE:AIDR
Rocket Doctor AI
0.62
0.19
42.53%
TSE:UDOC
UniDoc Health Corp
0.09
-0.23
-71.88%
TSE:DMED
DiagnaMed Holdings Corp.
0.12
0.09
283.33%
PanGenomic Health, Inc. Class A Corporate Events
Private Placements and Financing
PanGenomic Health Launches $2 Million Private Placement to Bolster Working Capital and Reduce Debt
Positive
Dec 30, 2025
PanGenomic Health Inc. has announced a non-brokered private placement of up to 4,000,000 units at $0.50 per unit, for total gross proceeds and debt settlement of up to $2 million. Each unit comprises one Class A common share and one warrant exerci...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
PanGenomic Health Enters Agreement with Ayla BioScience for Exclusive Distribution
Positive
Nov 6, 2025
PanGenomic Health Inc. has signed a non-binding letter of intent with Ayla BioScience to establish an exclusive distribution agreement and a share purchase agreement. This collaboration will allow PanGenomic to distribute Ayla’s Zeotech prod...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.